AI Discovery Platform BioMap offers a scalable AI for life sciences platform built on large foundation models and proprietary data from in-house high-throughput labs. This enables pharma and biotech clients to accelerate target discovery, protein design, and synthetic biology across multiple modalities. Flexible collaboration models make it easier for large enterprise or CROs to engage with BioMap.

Asia Expansion BioMap is expanding into Asia with a Hong Kong Innovation Hub and a Baidu-backed computation partnership, reinforced by HKIC funding and a planned Hong Kong IPO. This creates near-term opportunities to partner with APAC pharma, biotech startups, and research institutions seeking AI-enabled discovery capabilities, as well as potential co-investment or co-development deals.

Multimodal AI BioMap's xTrimo V3 multimodal foundation model, showcased at industry events, is designed to integrate diverse data types (structure, sequence, imaging) to accelerate life sciences discovery. The scale and HPC backing from Baidu positions BioMap to offer faster iteration cycles and differentiated performance for customers pursuing complex targets.

ADC Collaboration Strategic collaboration with GeneQuantum to develop next-generation ADC therapeutics, plus integration with GQ expertise, creates a focused path to pharma partners pursuing ADC programs. BioMap can offer joint AI-enabled discovery and ADC development services, expanding its addressable market in oncology and precision medicine.

Proprietary Data Proprietary data assets generated by BioMap’s high-throughput labs underpin model quality and defensibility, enabling data-driven partnerships and potential data licensing opportunities. This data moat can help attract long-term collaborations with pharma and biotech firms seeking reliable, scalable AI-assisted discovery pipelines.